Skip to main content
Premium Trial:

Request an Annual Quote

Coriell Using Affy's DMET in Gene/Drug Interaction Studies

NEW YORK (GenomeWeb News) — The Coriell Personalized Medicine Collaborative will use Affymetrix's DMET Plus biomarker panel for a national study of markers for drug response, Affy said today.

The CPMC, a branch of the Coriell Institute for Medical Research, is using the panel to expand studies it has already been conducting with Affy's Genome-Wide Human SNP Array 6.0 to identify genes that are associated with complex health conditions, such as diabetes, cancer, and heart and blood vessel diseases.

The DMET Plus panel includes an array, reagents, and software, and the company said it offers a cost-effective method for measuring variations in genes associated with drug metabolism and transport.

The CPMC's intent is to enroll 10,000 individuals by the end of the year, and ultimately 100,000, in an effort to understand why some subpopulations and individuals respond differently to a drug than anticipated.

Affy said that five organizations are now using the DMET Plus for pharmacogenomic studies and that 18 more organizations are scheduled to be trained on the platform.

Financial terms of the agreement were not released.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.